Integrated Report 2017
Integrated Report
-------------
Company Introduction
Materiality
The driving force of Eisai “human health care (hhc)”
Eisai’s Strengths in the Dementia Area
History of Eisai
Eisai’s Value Creation Process and Flow
Major Products
Management Strategies
CEO Message
Medium-Term Business Plan ‘EWAY 2025’
CTO Message
hhc Special Feature “Solution with Patients” Program Global hhc Best Practices
CFO Message
Value Creating Activities
Message from Corporate officers
6 “Ricchi” and Ongoing Projects
Development of New Potential Dementia Treatments
Initiatives for Dementia Area Offering Solutions that Go Beyond Providing Pharmaceuticals
Global Brand: Fycompa, BELVIQ
Message from Corporate officers
2 “Ricchi” and Ongoing Projects
Global Brand: Lenvima, Halaven
Global Drug Creation Activities
Major R&D Pipeline
Intellectual Property Strategies
Global Marketing Organization
Global Production System
Improving Access to Medicines (ATM)
Business Base (Related to ESG)
Initiatives for Sustainable Development Goals(SDGs)
Corporate Governance System
Interview with Outside Director
Board of Directors and Executive Officers
Compliance & Risk Management
Initiatives for Human Rights, Development of Working Environment and Occupational Safety and Health
Social Contribution Activities
Initiatives for Pharmaceutical Product Safety and Side Effects
Eisai’s Partnership Initiatives
Business with Consideration for the Global Environment
Appendix
Consolidated Financial Highlights Results for Fiscal 2016
ESG Index
Fundamental Knowledge and Terminology for Pharmaceutical Industry
Status of Shares
Corporate Information
Page
of
Save this page
My favourite pages
Download center
Send to a friend
Help
Iframe content
Page
of
Powered by ©
Euroland.com
Page saved
Page already saved
Page deleted
No saved pages